Pellegrini A, Massidda B, Pellegrini P, Defraia E, Usai A, Parrinello L, Bruni G, Rigamonti G, Sacchetti G
Int J Clin Pharmacol Ther Toxicol. 1983 Sep;21(9):483-6.
Single doses of indoprofen (400 mg, i.v.), morphine hydrochloride (10 mg, i.m.), and placebo were given to 12 women with moderate to severe tumor pain, mainly due to bone involvement, according to a Latin square design. Analgesic response, along with serum prolactin (PRL) and growth hormone (GH) levels, were measured after each treatment under double-blind conditions. Indoprofen and morphine were not significantly different as regards pain relief, but both were significantly more effective than placebo. Unlike morphine, however, indoprofen did not raise PRL. GH levels did not change following any treatment. In a second study indoprofen (400 mg, i.v., three times daily for 7 days) did not modify the PRL response to thyrotropin-releasing hormone nor serum GH levels. On the basis of the above findings it is suggested that indoprofen may be a safe alternative to opiates for relief of moderate to severe pain in women with breast tumors suspected of being prolactin-dependent.
按照拉丁方设计，对12名主要因骨转移而患有中度至重度肿瘤疼痛的女性给予单剂量的吲哚美辛（400毫克，静脉注射）、盐酸吗啡（10毫克，肌肉注射）和安慰剂。在双盲条件下，每次治疗后测量镇痛反应以及血清催乳素（PRL）和生长激素（GH）水平。吲哚美辛和吗啡在缓解疼痛方面无显著差异，但两者均比安慰剂显著有效。然而，与吗啡不同，吲哚美辛不会升高PRL。任何治疗后GH水平均未改变。在第二项研究中，吲哚美辛（400毫克，静脉注射，每日三次，共7天）并未改变PRL对促甲状腺激素释放激素的反应，也未改变血清GH水平。基于上述发现，提示吲哚美辛可能是怀疑为催乳素依赖性乳腺肿瘤女性缓解中度至重度疼痛的一种安全的阿片类药物替代物。
